Agentix (AGTX) Operating Expenses (2013 - 2026)
Agentix's (AGTX) quarterly Operating Expenses came in at $54285.0 in Q1 2026, down 68.46% YoY from $172121.0 in Q1 2025, and down 19.53% on a QoQ basis from $67463.0 in Q4 2025.
Agentix (AGTX) Operating Expenses (2013 - 2026) Analysis & Trends
Agentix (AGTX) has 14 years of Operating Expenses data on file, last reported at $54285.0 in Q1 2026.
- Quarterly Operating Expenses fell 68.46% year-over-year to $54285.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $445187.0 (down 13.26% YoY) and the FY2026 annual result came in at $445187.0, down 13.26% from the prior year.
- Operating Expenses retreated to $54285.0 in Q1 2026, from $67463.0 in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $2.0 million in Q1 2022 to a low of -$25326.0 in Q1 2024.
- A 5-year average of $299550.2 and a median of $164654.0 in 2022 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2024 — Operating Expenses sank 105.9% — and 2025, when it jumped 779.62%.
- Tracing AGTX's Operating Expenses over 5 years: stood at $353638.0 in 2022, then tumbled by 95.52% to $15846.0 in 2023, then soared by 510.97% to $96815.0 in 2024, then tumbled by 30.32% to $67463.0 in 2025, then decreased by 19.53% to $54285.0 in 2026.
- The last three Operating Expenses figures came in at $54285.0 (Q1 2026), $67463.0 (Q4 2025), and $123097.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | 95,504.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95,504.00 |
| Mar 31, 2026 | 54,285.00 |
| Dec 31, 2025 | 67,463.00 |
| Sep 30, 2025 | 123,097.00 |
| Jun 30, 2025 | 200,342.00 |
| Mar 31, 2025 | 172,121.00 |
| Dec 31, 2024 | 96,815.00 |
| Sep 30, 2024 | 93,010.00 |
| Jun 30, 2024 | 151,305.00 |
| Mar 31, 2024 | -25,326.00 |
| Dec 31, 2023 | 15,846.00 |
| Sep 30, 2023 | 353,155.00 |
| Jun 30, 2023 | 401,135.00 |
| Mar 31, 2023 | 429,134.00 |
| Dec 31, 2022 | 353,638.00 |
| Sep 30, 2022 | 424,330.00 |
| Jun 30, 2022 | 164,654.00 |
| Feb 28, 2022 | 2.02 Mn |
| Nov 30, 2021 | 166,750.00 |
| Aug 31, 2021 | 244,105.00 |